FindTrial
Sign In

Zelvina 15 mg hard capsules

DRUG8 trials

Sponsors

Incyte Corp., Sanofi-Aventis Recherche & Developpement, Pfizer Inc., Glaxosmithkline Research & Development Limited

Conditions

CancerDiffuse large B-cell lymphoma (DLBCL)Multiple MyelomaMultiple myelomaPlasma cell myelomafollicular lymphoma (FL) and marginal zone lymphoma (MZL)

Phase 1

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)–DREAMM5.
Active, not recruitingCTIS2023-509550-55-00
Glaxosmithkline Research & Development LimitedMultiple Myeloma
Start: 2020-01-21Target: 62Updated: 2025-10-10

Phase 2

International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study
Active, not recruitingCTIS2023-507180-19-00
Sanofi-Aventis Recherche & DeveloppementCancer
Start: 2023-04-05Target: 37Updated: 2025-12-01

Phase 3

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Active, not recruitingCTIS2023-505579-53-00
Incyte Corp.Diffuse large B-cell lymphoma (DLBCL)
Start: 2022-10-25Target: 74Updated: 2025-07-24
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Active, not recruitingCTIS2023-504684-16-00
Incyte Corp.follicular lymphoma (FL) and marginal zone lymphoma (MZL)
Start: 2021-06-05Target: 345Updated: 2025-10-02
A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
Active, not recruitingCTIS2023-507419-37-00
Sanofi-Aventis Recherche & DeveloppementPlasma cell myeloma
Start: 2020-06-25Target: 272Updated: 2025-10-06
C1071007 - MAGNETISMM-7 A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Active, not recruitingCTIS2023-508897-27-00
Pfizer Inc.Multiple Myeloma
Start: 2022-04-28Target: 377Updated: 2025-11-27
C1071006 – An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible or Transplant-Deferred Participants With Newly Diagnosed Multiple Myeloma
RecruitingCTIS2024-514139-50-00
Pfizer Inc.Multiple myeloma
Start: 2022-11-14Target: 558Updated: 2025-12-04
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide and Dexamethasone versus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Active, not recruitingCTIS2024-514417-34-00
Sanofi-Aventis Recherche & DeveloppementCancer
Start: 2017-12-14Target: 308Updated: 2025-05-12